FoxO transcription factors are an evolutionary conserved subfamily of the forkhead transcription factors, characterized by the forkhead DNA-binding domain. FoxO factors regulate a number of cellular processes involved in cell-fate decisions in a cell-type-and environment-specific manner, including metabolism, differentiation, apoptosis and proliferation. A key mechanism by which FoxO determines cell fate is through regulation of the cell cycle machinery, and as such the cellular consequence of FoxO deregulation is often manifested through perturbation of the cell cycle. Consequently, the deregulation of FoxO factors is implicated in the development of numerous proliferative diseases, in particular cancer.
Introduction
The development of multicellular organisms demands an increase in cell type and complexity, often leading to the evolutionary expansion and diversification of protein families. Since the founding member of the forkhead box transcription factor family, FoxA, was cloned and characterized in the fruitfly Drosophila melanogaster (Weigel et al., 1989) , at least 17 subclasses of Fox transcription factors have been identified in humans. The FoxO family is symptomatic of the increase in complexity required for the development of higher organisms. Whereas only one FoxO analogue (Daf-16) has been identified in Caenorhabditis elegans, four FoxO isoforms have so far been identified (FoxO1, FoxO3a, FoxO4 and FoxO6) in mammalian cells (Greer and Brunet, 2005) . Recent evidence would suggest that these FoxO isoforms display both redundancy and compensation in vivo, while retaining isoform-specific roles in certain cell lineages, despite sharing common consensus DNA-binding motifs and other functional domains.
Despite the diversification of FoxO family, a evolutionary conserved feature of FoxO transcription factors is that they function as downstream effectors of the phosphoinositide 3-kinase (PI3K)-protein kinase B (PKB also called Akt) pathway (the Age-1-Akt analogues in C. elegans) (Burgering and Kops, 2002) . The PI3K-PKB signalling cascade is a key pathway by which cells may respond to a wide range of stimuli, which may be generated intrinsically (for example, growth factors, cytokines and cell-cell contact) or from an external source (for example, irradiation, and physical or genotoxic stress) (Leevers et al., 1999; Hennessy et al., 2005; Wymann and Marone, 2005; Samuels and Ericson, 2006) . At the molecular level, many of the PI3K-PKB-mediated mitogenic responses are achieved through the direct repression of FoxO transcription factors by PKB-mediated phosphorylation, promoting nuclear export, proteosomal degradation and a decrease in transactivation activity (Brunet et al., 1999 (Brunet et al., , 2001 Kops et al., 2002b; Jacobs et al., 2003) . FoxO is also a target of many other kinases, including serum and glucocorticoid-regulated kinase, c-Jun N-terminal kinase, a dual specificity tyrosinephosphorylated and regulated kinase (DYRK1A), CDK2 and IkB kinase (Brunet et al., 1999 (Brunet et al., , 2001 Kops et al., 2002b; Jacobs et al., 2003; Greer and Brunet, 2005) and the deregulation of PKB and these kinases is frequently observed in proliferative disorders and can contribute significantly to tumorigenesis (Hennessy et al., 2005; Samuels and Ericson, 2006) . The intimate link between FoxO signalling and regulation of cell cycle control is highlighted by the fact that in these instances the re-introduction of FoxO expression, for example in PTEN-deficient tumours, can induce cell cycle arrest followed by cell death (Nakamura et al., 2000) . This review will aim to describe both the mechanisms by which FoxO proteins regulate cell cycle progression and effect checkpoint control, and how the role of these pathways in other physiological processes, such as senescence, cell differentiation and apoptosis, which may play a role in cancer development and progression. Moreover, we will discuss the role of the cell cycle when considering FoxO as a potential therapeutic target.
FoxO transcription factors and cell cycle control
Cell proliferation involves entry into the cell cycle from a resting or quiescent state (G0 phase) and successful progression through G1 (gap phase 1), S (DNA synthesis), G2 (gap phase 2) and M (mitosis) of the cell cycle. The phase transitions of the cell cycle are under stringent control by a complex set of cell cycle regulatory proteins, and progression through each phase of the cell cycle is controlled primarily by the cooperative activity of specific cyclin-dependent kinases (CDKs), and their regulatory subunits, the cyclins (Sherr, 1996; Sherr and Roberts, 1999) . In fact, one of the first functions discovered for mammalian FoxO proteins was their ability to regulate the G1/S phase transition Dijkers et al., 2000b) (Figure 1 ).
FoxO and the G1/S phase transition
The progression of the cell cycle from G1 to S phase is dependent primarily upon the activation of E2F transcription factors through the sequential hyperphosphorylation of the retinoblastoma (pRB) family of proteins (that is, pRB, p107 and p130) mediated by the cyclin-D/E-CDK complexes. During early G1 phase, the expression levels of D-type cyclins are upregulated by mitogenic signals, leading to increased levels of active D-type cyclin-CDK4/6 complexes (Sherr, 1995 (Sherr, , 1996 Sherr and Roberts, 1999) . In fact, the D-type cyclins are the first components of the cell cycle machinery to be induced in response to mitogenic stimulation, thus providing a link between proliferative signals and the cell cycle. These cyclin D-CDK4/6 holoenzymes are believed to be crucial for driving cells through the restriction point (Matsushime et al., 1992; Bates et al., 1994; Meyerson and Harlow, 1994) , a location at late G1 phase after which cells often become independent of growth factors and refractory to inhibitory signals. Overexpression of the constitutively active nuclear form of FoxO1 or FoxO3a has been shown to repress CDK4 activity and induce cell cycle arrest at G1 phase (Ramaswamy et al., 2002; Schmidt et al., 2002) . Conversely, ectopic expression of cyclin D1 can partially overcome the FoxO-induced cell cycle arrest, implicating the downregulation of D-type cyclins as a mechanism of FoxO-induced cell cycle inhibition (Ramaswamy et al., 2002) . At present, there is no evidence supporting FoxO proteins suppress D-type cyclin expression through direct binding to their gene promoters; however, FoxO proteins can indirectly downregulate D-type cyclins by upregulating the transcription repressor Bcl-6, a known transcriptional repressor of cyclin D2 gene (Fernandez de Mattos et al., 2004) . It is also worth mentioning that the PI3K-PKB signalling pathway has been directly implicated in both cyclin D1 gene transcription and protein stabilization (Diehl et al., 1998; Muise-Helmericks et al., 1998; Gille and Downward, 1999 ). Thus, an elevated level of PI3K-PKB activity, coupled with the concomitant FoxO inactivation will induce cyclin D1 at multiple levels, resulting in aberrantly high levels of cyclin D1-CDK4/6 activities and premature S phase entry. Nevertheless, current evidence would suggest that regulation of cyclin D expression is not the sole mechanism through which FoxO regulates G1/S phase transition and that regulation of G1/S phase transition by FoxO also relies heavily upon the cyclin-dependent kinase inhibitors (CKIs).
Cyclin-dependent kinase inhibitors function through inhibiting the activity as well as the assembly of cyclin-CDK complexes. There are two distinct classes of CKIs, the Cip/Kip family (that is, p21
Cip1
, p27
Kip1 and p57
Kip2
) and the INK4 family (that is, p15
INK4b , p16
INK4a
, p18
INK4c and p19 1NK4d ). While the Cip/Kip family members form inhibitory heterotrimeric complexes with cyclin-CDK, the INK4 members complex only with CDK4 and CDK6, and in doing so, excluding their cyclin D regulatory subunits Roberts, 1999, 2004; Sherr, 2001 ). FoxO proteins have been shown to directly upregulate the Cip/Kip members p21
Cip1 and p27
Kip1 transcription Seoane et al., 2004; Gomis et al., 2006; Katayama et al., 2007) , and thus may inhibit CDK-cyclin A, E and D activity. Hence, the rescue of FoxO-induced cell cycle arrest by the overexpression of cyclin D may result from a titration effect upon the CKIs upregulated by FoxO, rather than rescuing the transcriptional downregulation of cyclin D. Most recently, the two INK4 CDK4/6-specific inhibitors p15 INK4b and p19 INK4d have also been shown to be FoxO targets in inducing G1 cell cycle arrest (Katayama et al., 2007) . Consistent with this finding, The functional consequence of FoxO-mediated disruption of cyclin-CDK complex formation is to decrease the phosphorylation of the pRB family proteins, and hence E2F transcriptional activity. However, FoxO may also directly target the pRB family members p107 and p130 (also called pRB2) (Bandara et al., 1994; Giacinti and Giordano, 2006; Macaluso et al., 2006) ; mammalian FoxO3a and FoxO4 have been shown to directly activate the transcription of the p130 gene, which can induce cells to undergo cell cycle arrest and enter a quiescent state (Kops et al., 2002b) . Interestingly, some cell cycle regulators, including p107, pRB, E2F1-3, cyclin D1, cyclin E1/2, cyclin A1/2, CDK2 and CDC2 are themselves transcriptional targets of E2F-and pRBrelated proteins (Dalton, 1992; Furukawa et al., 1994; Shan et al., 1994; Ohtani et al., 1995; Schulze et al., 1995; Sears et al., 1997; Araki et al., 2003; Cobrinik, 2005) . During cell cycle entry, the cyclin D-CDK4/6 kinase has been shown to trigger pRB protein partial phosphorylation, resulting in the derepression of a small number of E2F genes, including cyclin E. Expression of cyclin E then activates CDK2 to further phosphorylate the pRB proteins, leading to the expression of the full array of E2F-regulated cell cycle regulatory genes. Therefore, FoxO-mediated D-type cyclin repression, CKI and p130 activation will ultimately lead to the downregulation of a whole host of E2F-regulated cell cycle regulators essential for cell cycle entry. It is therefore evident that FoxO activation can directly induce multiple changes in factors associated with G1/S phase transition, through downregulating activating factors and upregulating repressors, cumulating in the inhibition of E2F transcriptional activity.
FoxO and G2/M phase transition During G1/S phase transition, cells pass through the restriction point and become committed to cell cycle progression, and often independent of growth factors and refractory to inhibitory signal. However, cell cycle arrest at the G2/M checkpoint is a critical component of stress response, allowing DNA damage repair (Kaufmann, 1995; Molinari, 2000; Stark and Taylor, 2006) . Moreover, deficiencies in the G2/M phase checkpoint control are often associated with genomic instability and tumorigenesis (Lobrich and Jeggo, 2007) . FoxO transcription factors have also been reported to have a role in the late phases of the mammalian cell cycle. Activation of FoxO3a during S phase transition will induce a G2/M cell cycle arrest, although this effect may not be mutually exclusive with the regulation of G1/S phase transition by FoxO. In contrast, a prior report has demonstrated that FoxO proteins activate the expression of genes, such as cyclin B and polo-like kinase, important for G2 and M phase progression (Alvarez et al., 2001) . If this were true, then FoxO expression would appear to arrest cells at G1, while at the same time promoting cell cycle progression during G2 and M phases. However, subsequent microarray evidence has revealed that the overexpression of FoxO1 decreases the expression of genes (for example, CDK2, cyclin B1, cyclin B2, CDC2 and NEK2) essential for G2 and M transition, although the mode of action is yet to be fully determined (Takano et al., 2007) . Cyclin G2, an unconventional cyclin that facilitates G2/M arrest by inhibiting the cyclin B/CDC2(CDK1) complex, has also been identified as the direct target of FoxO proteins (Martinez-Gac et al., 2004) . Moreover, in response to DNA damage, FoxO3a has also been shown to activate the expression of the growth arrest and DNA damage response gene GADD45a to mediate G2/M cell cycle arrest and trigger DNA repair (Tran et al., 2002) . Recently, one of the pro-survival Bcl-2 family members, Bcl-XL, which is an important downstream target of FoxO (Tang et al., 2002) , has been shown to colocalize and bind to CDC2 during G2/M phase progression and its overexpression stabilizes a G2/M arrest senescence programme in surviving cells after DNA damage (Schmitt et al., 2007) . Thus, these data would suggest that FoxO can directly regulate a series of cell cycle proteins, and depending on stimuli, control both G1/S and G2/M phase progression. However, while it is evident that FoxO activation can directly induce multiple changes in cell cycle regulatory factors, evidence is also emerging of a complex transcriptional network in which the regulation of cell cycle progression by FoxO requires the direct binding to other transcriptional factors and/or cofactors, in a process that may be disrupted during tumorigenesis and contribute to disease development.
FoxO transcriptional networks and cell cycle
The transforming growth factor b (TGFb) superfamily of cytokines regulates a wide variety of cellular functions, including cell cycle progression, and deregulation of this pathway is associated with tumorigenesis. For example, TGFb has been reported to inhibit the proliferation of primary malignant epithelial cells, by inducing cell cycle arrest through activation of the Smad group of transcription factors, which are frequently mutated in tumours (Miyaki and Kuroki, 2003) . Evidence would suggest that a key component of TGFb signalling is the formation of a Smad-FoxO3a complex, which is required to induce the expression of the p21 Cip1 gene (Seoane et al., 2004) . In addition, the p15
INK4b gene has also been demonstrated to be target of the FoxOSmad complex, in a mechanism dependent upon the CCAAT/enhancer-binding protein b (C/EBPb) transcription factor (Gomis et al., 2006) . The regulation of the FoxO-Smad complex by C/EBPb may be disrupted during tumorigenesis; the cytostatic effects of TGFb are lost in half of the metastatic breast cancer patient cells as a result of the expression of high levels of the C/EBPb inhibitory isoform LIP. In addition to regulating G1/S phase transition, FoxO-Smad complexes have also been implicated in regulating the G2/M checkpoint by acting as co-regulators of the stress response genes in keratinocytes, including GADD45a and GADD45b, which have a role in G2/M cell cycle control. Thus, FoxO represents a point of convergence of the PI3K-PKB pathway with the TGFb signalling cascade to regulate cell cycle progression. Interestingly, the induction of p21
Cip1 expression by the FoxO-Smad complexes is antagonized by another forkhead subfamily member FoxG1 during the development of the telencephalic neuroepithelium and in glioblastoma brain tumour cells, suggesting that the Fox families may interact to determine cell fate (Seoane et al., 2004) . Moreover, the tissue-specific expression pattern of FoxG1, primarily being found in brain tissue, points to a scenario whereby the cell lineage influences not only the outcome but also the regulation of FoxO signalling.
In fact, it is becoming apparent that FoxO may interact with other Fox proteins to influence cell cycle. For example, a recent transcriptional profiling study identified FoxM1 to be repressed by FoxO3a (Delpuech et al., 2007) and it was shown that the FoxM1 gene expression can be negatively regulated by a FoxO3a target gene Mxi1 (Delpuech et al., 2007) . FoxM1 has a critical function in G2 and M transition by regulating the expression of various G2/M cell cycle regulatory genes, including polo-like kinase, cyclin B, cyclin A, CDC25B and CDC2 (Wang et al., 2002a, b; Yoshida et al., 2007) , and loss of FoxM is associated with G2/M checkpoint arrest and loss of mitotic spindle integrity (Laoukili et al., 2005; Wonsey and Follettie, 2005) . Overexpression of FoxM1 through chromosomal amplification or the activation of transcription, for example, through Gli-1 is associated with the development and progression of many cancer types, including cancers of the breast, liver, prostate, brain and lung (Teh et al., 2002; Kalinichenko et al., 2004; Kalin et al., 2006; Kim et al., 2006; Liu et al., 2006; Madureira et al., 2006) . Other mechanisms of interaction may exist between FoxM1 and FoxO3a. For instance, the inhibition of FoxO may also be associated with the activation of FoxM1; DYRK1 inhibits FoxO (Woods et al., 2001) , while also activating Gli-1, and thereby promoting FoxM1 expression. In addition, FoxO3a-induced expression of CKIs may inhibit CDK-cyclin complexes, which are required for the activation and nuclear localization of FoxM1 (Wang et al., 2002a (Wang et al., , b, 2005 Luscher-Firzlaff et al., 2006; Wierstra and Alves, 2006) . However, while induction of FoxO may repress FoxM1 expression, the significance of this repression for the FoxO-induced cell cycle arrest and/or apoptosis remains to be determined. Moreover, current evidence would suggest that the regulation of CKIs and pro-apoptotic genes by FoxO are primarily responsible for these cellfate outcomes. However, the interaction between FoxM and FoxO remains an intriguing prospect, and the equilibrium between proliferation and cell cycle arrest may be maintained in part by cooperation and interaction of these factors. For example, in addition to FoxObinding oestrogen receptor in breast cancer cells (Schuur et al., 2001; Zhao et al., 2001) , which is critical in regulating the proliferation and differentiation of breast tissue, evidence suggests that FoxM1 and FoxO3a may cooperate to regulate ERa gene transcription .
FoxO, cell cycle, senescence and lifespan
FoxO-cellular senescence Cellular or replicative senescence is believed to be an important mechanism of tumour suppression, and FoxO has a crucial role in regulating this process by controlling the expression of a number of cell cycle regulators. PI3K inhibition using chemical inhibitors, such as wortmannin or LY294002, can induce a cell cycle arrest similar to cellular senescence in primary mouse embryo fibroblasts (Collado et al., 2000) , through FoxO-induced p27
Kip1 expression. Moreover, overexpression of FoxO or p27
Kip1 in primary mouse embryo fibroblasts can recapitulate this phenotype, promoting premature cell cycle arrest, changes in cell morphology, increases in senescence-associated b-galactosidase activity and decreased ability to re-enter cell cycle in response to mitogenic stimulation. FoxO also targets p130, but does so primarily in the absence of p27 Kip1 , through a compensatory mechanism by which p130 can functionally substitute for the loss of p27 Kip1 (Collado et al., 2000) . The ability of FoxO to induce G0/G1 arrest is lessened in p27
Kip1 and p130 doubledeficient fibroblasts (Kops et al., 2002b) , suggesting that both p27
Kip1 and p130 are important for mediating FoxO-dependent, cellular senescence-associated G0/G1 arrest. Further evidence for a role of FoxO in cellular senescence is supported by a recent in vivo study by Courtois-Cox et al. (2006) , demonstrating that oncogene-induced senescence also involves the repression of the PI3K-PKB signalling pathway and induction of FoxO. In the report, the authors provided experimental evidence that oncogene-induced senescence occurs in vivo using a ras oncogene hyperactivation system triggered by NF1 functional deletion and showed that senescent population of cells can be detected in vivo in benign and not advanced tumours, supporting a genuine role of cellular senescence in tumour suppression, especially during early carcinogenesis and hyperplasia. This oncogene-induced cellular senescence has also been shown to be mediated through the repression of the PI3K-PKB signalling pathway. Moreover, the expression of a constitutively activated FoxO1 mutant, which cannot be inactivated by PKB, rapidly triggered cellular senescence associated with the hypophosphorylation and thus activation of the retinoblastoma protein pRB, a hallmark for G0/G1 cell cycle arrest. These discoveries highlight the pivotal role of FoxO-mediated cell cycle arrest in cellular senescence and tumour suppression.
FoxO-stem cell renewal
In addition to being a potent tumour suppressor mechanism, cellular senescence also functions to control the proliferative competence of stem cell and progenitor pools. The cell cycle has an essential function in controlling self-renewal during stem cell development, and this is particularly evident in the stem cells of the haematopoietic system, a tissue with high volumes of cell turnover. An important feature of haematopoietic stem cells (HSCs) is their ability to maintain a resting, or quiescent state (G0), only entering the cell cycle after long intervals, and thereby preventing proliferative exhaustion (Myatt and Lam, 2007a) . Recent evidence suggests that FoxO family members play a critical role in maintenance of the HSC pool; simultaneous deletion of three FoxO isoforms in the HSCs of mice led to a significant rise in the numbers of the mature peripheral blood cells, and an expansion of haematopoietic cells of myeloid, lymphoid and erythroid origins (Tothova et al., 2007) . Conversely, the bone marrow of FoxO-null mice possessed a smaller HSC pool, which is required for sustaining the haematopoietic system. This decrease in HSCs is associated with a reduced ability to repopulate recipient bone marrow after serial transplantations and a reciprocal increase in the number of more differentiated haematopoietic populations. This was paralleled by an increased exit from quiescence and a higher rate of cell proliferation. These observations are consistent with previous in vitro studies showing that FoxO activation can culminate in a G0/G1 cell cycle arrest mediated by transcriptional regulation of p21 Cip1 , p27 Kip1 , cyclin D and p130. Taken together, these results indicate that the ability of FoxO to induce cell arrest in HSC is linked to an ability to preserve self-renewal potential, preventing premature ageing and excess differentiation of HSCs. It is generally believed that CKIs, such as p21
Kip1
, set the stoichiometric thresholds for cell cycle entry and progression through G1 in response to mitogenic stimuli, such as cytokines and interactions with their microenvironments. Experimental evidence from p21 Cip1 -and p27
-deficient mice suggests that these CKIs have specific roles in the regulation of quiescence of HSCs and progenitors, respectively. For instance, p21 Cip1 -deficient mice exhibit an increase in HSC cell cycle entry and exhaustion upon transplantation, suggesting a role for p21
Cip1 in HSC quiescence (Cheng et al., 2000b) . In contrast, p27
Kip1 knockout mice display increased progenitor, but not HSC, populations (Cheng et al., 2000a) . Indeed, evidence suggests that p21
Cip1 and p27 Kip1 are critical regulators of the increased HSC-specific entry into the cell cycle observed in the FoxO isoform-deficient mice. Although p130 deletion alone has little effect on HSC and more mature progenitor development, in p27
Kip1 and p130 doubledeficient mice there is an increased in cellularity of the more mature lymphoid, erythroid and myeloid haematopoietic cells (Soeiro et al., 2006) . Similar haematopoietic-related defects are detected for other FoxO-regulated cell cycle regulatory genes, including cyclin Ds and Ink4s (Myatt and Lam, 2007a) . For example, mouse embryos that lack all three D-type cyclins, or both CDK4 and CDK6, die of haematopoietic abnormalities after day E14.5 (Myatt and Lam, 2007a) . In summary, the finding that FoxO deletion specifically affects HSC renewal and progenitor development is probably due to the fact that FoxO regulates genes controlling early cell cycle phases when the decisions to proliferate and differentiate are made, reflecting the particular importance of the G1 checkpoint in regulating the high volumes of cell turnover observed in the haematopoietic system.
FoxO-organismal senescence and longevity
FoxO proteins also have a central role in regulating organismal ageing (senescence), but the outcomes of FoxO activation appear to be different from those for cellular senescence. In multicellular organisms, FoxO proteins function to induce cell cycle exit, and thereby counteracting senescence and promoting longevity. For example, in C. elegans, dauer is the long-lived species compared with larva, and its formation is induced by food deprivation or stress. Dauer formation requires the activation of the FoxO homologue Daf-16 to induce G0/G1 cell cycle arrest through the induction of the nematode Cip/Kip inhibitor, Cki-1 (Boxem and van den Heuvel, 2001 ). Expression of Cki-1 can induce prematurely cell cycle arrest in G1, whereas knocking down of Cki-1 activity by RNA interference promotes S phase entry (Boxem and van den Heuvel, 2001) . It is also worth mentioning that this role of FoxO is also conserved in the fruitfly Drosophila (Kramer et al., 2003) . When nutrients are limited, the insulin-insulinlike growth factor (IGF) signalling pathway is repressed and the activated dFoxO promotes G1 cell cycle arrest but lengthens lifespan (Giannakou et al., 2004) . Consistently, expression of dFoxO during early larval development causes inhibition of larval growth (Giannakou et al., 2004) . Thus, in terms of longevity of a eukaryotic multicellular organism, FoxO causes cell cycle arrest, but at the same time increases the lifespan. Recent data identifying Daf-16-regulated genes in C. elegans support this notion; 29 Daf-16/FoxOregulated genes were identified that act in the insulin-IGF-1 pathway to influence tumour growth, and are likely to act in a cumulative manner to influence tumour growth (Pinkston-Gosse and Kenyon, 2007). Interestingly, a large proportion of genes that affect tumour growth also affect the normal lifespan of C. elegans. Perhaps the most intriguing question arises from the parallels between p53 and FoxO (van der Horst and Burgering, 2007). In the above study, inhibiting the upregulation of nuclear pore genes by Daf-16 blocked p53-dependent, but not independent, cell death (Pinkston-Gosse and Kenyon, 2007) . In contrast to the current understanding of the role of FoxO in C. elegans, activation of p53 reduces lifespan in mouse models, but decreases cancer incidence, supporting a system of antagonistic pleiotropy (van der Horst and Burgering, 2007) . Interestingly, both FoxO3a and p53 are regulated by a similar profile of post-translational modifications and influence cell cycle through the regulation of GADD45 and p21
Cip1
. Thus, p53 and FoxO may influence tumour suppression and longevity, and a balance in activity may be controlled in part by a negative feedback loop between the two proteins.
Indeed, p53 may induce the expression of serum and glucocorticoid-regulated kinase, resulting in the phosphorylation and nuclear exclusion of FoxO3a (Maiyar et al., 1996) , and FoxO3a may inhibit p53-mediated repression of SIRT1 expression, which binds to, and deacetylates p53. (Campisi, 2005; van der Horst and Burgering, 2007) . Thus, the regulation of the cell cycle by FoxO3a may play an important role in longevity and tumour suppression, in an intriguing and complex manner, which demands further investigation.
FoxO, cell cycle arrest and cell-fate decisions
FoxO-cell cycle and differentiation As well as playing an active role in the G1 checkpoint of the cell cycle, CKIs are also important regulators in mediating cell cycle arrest that precedes differentiation and apoptosis. Cumulative data from mouse and nematode studies point to a critical role of FoxO3a in differentiation, primarily through modulation of the cell cycle machinery, and a key feature of both is the regulation of FoxO3a by pro-survival and nutrient responsive pathways, respectively.
After hatching, C. elegans only commence development in the presence of nutrients, and in a nutrient-deprived environment the larvae remain in a developmentally arrested state (L1 arrest). Critically, mutants lacking Daf-16, the C. elegans homologue of the mammalian FoxO transcription factors, fail to arrest cell cycle and development leading to rapid lethality in the absence of nutrients. The failure of Daf-16 mutants to arrest at L1 is at least partly due to their failure to activate the transcription of the nematode Kip/Cip CKI, Cki-1, in the larval stem cells in response to starvation (Baugh and Sternberg, 2006) . In mammals, the PI3K-PKB cascade is the major pro-survival nutrient responsive pathway, which has been demonstrated to be a critical regulator of b-cell mass in the pancreas (Holz and Chepurny, 2005) , and mice lacking functional FoxO1 in the pancreas are diabetic and have a lower pancreatic islet b-cell mass (Martinez et al., 2006) . In a manner reminiscent of nematode developmental defects, the disruption of FoxO signalling manifests primarily through cell cycle deregulation. Previous studies on D-type cyclin-deficient mice have shown that cyclin D2, and to a lesser extent cyclin D1, is required for adult b-cell proliferation (Kushner et al., 2005) . Furthermore, overexpression of a constitutively active PKB, the direct negative regulator of FoxO, in b-cells leads to cell proliferation, which is associated with increased cyclin D1 and D2 levels and CDK4 activity. Thus, these findings again provide evidence to suggest that in adult mammals and nematode larvae, disruption of FoxO leads to developmental defects associated with disruption of cell cycle through regulation of the CKIs and cyclin D family members, respectively. Indeed, gene knockout studies in mice have also revealed that the cyclin D gene family plays a central role in the regulation of the interplay between cell cycle and development by FoxO3a. For example, FoxO3a-deficient female mice are defective in ovarian follicular development, characterized by age-dependent infertility, and female mice lacking cyclin D2, one of the critical downstream targets of FoxO3a, are also sterile because of the inability of ovarian granulosa cells to proliferate normally in response to follicle-stimulating hormone (Sicinski et al., 1996) . In primary rat ovarian granulosa cells, cyclin D2 expression has been shown to be specifically induced by follicle-stimulating hormone via FoxO at transcriptional level . Taken together, these results indicate FoxO3a has a unique role in ovarian development, through modulating the expression of cyclin D2, and thus controlling cell cycle progression in the granulosa cells.
It is also becoming apparent that disruption of cell differentiation through FoxO3a deregulation has a critical role in the development of certain cancers. Expression of the oncogenic fusion protein Bcr-Abl, which is associated with the development of chronic myeloid leukaemia, downregulates FoxO activity through Bcr-Abl-induced PI3K-PKB hyperactivation. Besides uncontrolled proliferation, another defining characteristic of myeloid leukaemic cells is that they are trapped in an undifferentiated state. Overexpression of FoxO3a alone induces erythroid differentiation in leukaemic cells and this is in turn antagonized by ectopic expression of Id1 (inhibitor of differentiation 1), suggesting that FoxO3a promotes haematopoietic differentiation by targeting Id1. Indeed, in vivo Id1 gene promoter-binding assay showed that FoxO3a suppresses Id1 through direct binding to its promoter (Birkenkamp et al., 2007) . Interestingly, the FoxO3a-Id1 promoter interaction is dependent on the consensus forkhead DNA recognition element. How this interaction results in Id1 repression is not fully characterized, but it has been proposed that this repression is achieved through the recruitment of the histone deacetylase 1/mSin3a complex (PJ Coffer and EW Lam, unpublished work). In line with this positive role in the promotion of haematopoietic differentiation, FoxO3a has also been shown to induce erythroid differentiation and cellular senescence through Id1 (Birkenkamp et al., 2007) . Current evidence suggests that Id proteins also function downstream of c-myc, and promote cell cycle progression through upregulation of cyclin D1 expression and repression of p16INK4a expression, culminating in the inactivation of the p16
INK4a
-pRB tumour suppressor pathway (Swarbrick et al., 2005) . Thus, these findings establish FoxO proteins as key transcriptional regulators of the PI3K-PKB pathway that control the cell cycle, which in turn modulates cell proliferation and development. Similarly, transgenic and gene deletion studies have also shown that FoxO1 plays a crucial role in liver fibrosis, a process that causes hepatic stellate cells to transdifferentiate from a quiescent phenotype to a proliferating collagen-producing myofibroblast-like phenotype (Adachi et al., 2007) . Constitutively active FoxO1 has been demonstrated to inhibit hepatic stellate cell proliferation, via cell cycle arrest at the G1 phase, while dominant-negative FoxO1 promotes proliferation of hepatic stellate cells, even in the presence of the PI3K inhibitor LY294002. Furthermore, FoxO1 þ /À mice have been found to be more susceptible to liver fibrosis compared with their wild-type counterparts and may be associated with the induction of p27
Kip1 by FoxO1. It is interesting to note that FoxM1 is also a critical regulator of hepatic cell fate, and that while FoxO3a promotes differentiation and growth arrest, FoxM1 is required for hepatic cell proliferation and liver regeneration (Krupczak-Hollis et al., 2003; Wang et al., 2003) . Thus, whether FoxO1 may regulate FoxM1 expression in hepatic cells, in a manner similar to the regulation of FoxM1 by FoxO3a (Delpuech et al., 2007) , is an interesting and as yet unexplored proposition.
FoxO-cell cycle and apoptosis
Cell cycle checkpoints are activated in response to genotoxic stress induced by most chemotherapeutic drugs (Lukas et al., 2004; Bartkova et al., 2005) . Thus, in addition to preceding differentiation, cell cycle arrest may also be induced by genotoxic stress and lead to apoptosis. Indeed, most chemotherapeutic drugs are reported to arrest or delay cell cycle progression, and if the DNA damage or other cellular defects are extensive, the cell will undergo either apoptosis or cellular senescence (Lukas et al., 2004; Bartkova et al., 2005) . Moreover, cancer cells may be considered to display an enhanced or higher level of basal stress, such as increased levels of reactive oxygen species or stress kinase activity, and it is precisely the deregulation of cell cycle checkpoints that allow cancer cells to tolerate such cellular conditions, while simultaneously promoting genomic instability and tumour progression (Giles, 2006; Wu, 2006; Fruehauf and Meyskens, 2007) . One such mechanism by which cancer cells can tolerate cellular stress is the deactivation of FoxO3a, which would be anticipated to be activated by oxidative stress and stress kinases, both of which may converge through c-Jun N-terminal kinase-mediated phosphorylation of FoxO3a (Essers et al., 2004 (Essers et al., , 2005 Vogt et al., 2005; Huang and Tindall, 2007) . Thus, it is not perhaps surprising that the re-introduction of FoxO3a can induce tumour cell kill in cancer cells that have repressed FoxO3a activity (Modur et al., 2002) , and also that activation of FoxO transcription factors has a role in mediating the cytostatic and cytotoxic functions of chemotherapeutic drugs in some cancer types. However, the cell cycle arrest induced by FoxO can have an influence on the eventual outcome in terms of cell fate and may also promote DNA damage repair and stress resistance (Tran et al., 2002) . For example, it has been demonstrated that abolishing the cell cycle checkpoint can augment the efficacy of some of the anticancer chemotherapeutic drugs and increase the level of cell death (Teyssier et al., 1999; Kokkinakis et al., 2006) . In a similar manner, treatment of cells with radiation in combination with caffeine, which activates CDC2 through the CDC25C phosphatase, results in ablation of G2/M checkpoint and increased apoptosis (Russell et al., 1995; Yao et al., 1996) . FoxO family members have also been shown to promote mammalian cell survival by inducing cell cycle arrest and quiescence in response to oxidative stress Kops et al., 2002a, b; Brunet et al., 2004; Essers et al., 2004) . At the same time, the CDK inhibitor p27 Kip1 , the prominent downstream target of FoxO, which blocks progression of cells from late G1 to S phase, has also been implicated directly in the induction of apoptosis by FoxO (Wang et al., 1997; Wu et al., 1999; Dijkers et al., 2000b) . These observations illustrate the complexity of the interplay among cell cycle checkpoints, apoptosis and senescence (Figure 2) . It is most likely that the physiological response triggered by FoxO transcription factors is often determined by the cellular context as well as the cofactors involved.
Targeting FoxO as a therapeutic strategy--a role for cell cycle regulation A common feature of tumour development is the deregulation of cell cycle, leading to an uncoupling of the cell cycle machinery to apoptosis and differentiation. The critical role of FoxO proteins in cell cycle regulation and cell-fate determination makes these transcription factors an attractive target for therapeutic intervention. Indeed, recent evidence indicates that FoxO transcription factors play a key role in mediating the cytostatic and cytotoxic effects of various chemotherapeutic drugs. For example, paclitaxel (Taxol), an anticancer drug that targets the spindle checkpoint, activates FoxO3a in breast cancer cells to induce G2/M arrest and apoptosis (Sunters et al., 2003 (Sunters et al., , 2006 . Moreover, in paclitaxelresistant breast cancer cells the G2/M cell cycle checkpoint and apoptosis are uncoupled in the resistant cells, possibly through a loss of FoxO3a activation ( Sunters et al., 2003) . Thus, in this instance, the regulation of the G2/M checkpoint, and subsequent apoptosis, by FoxO3 is a critical component of paclitaxel-induced cell death. Regulation of the G2/M checkpoint by FoxO1 also plays a critical role in the response of cancer cells to the DNA damage-inducing topoisomerase I inhibitor agent irinotecan, CPT-11, which has been reported to induce G2/M cell cycle arrest, followed by senescence or apoptosis in colon carcinoma cells (Bhonde et al., 2006a, b) . In response to CPT-11, FoxO1 promotes G2/M cell cycle arrest and apoptosis independently of p53, and FoxO1 silencing diminishes CPT-11-induced cell cycle arrest and apoptosis . According to a recent report, FoxO may facilitate the cytostatic effect of CPT-11 via a mechanism involving the pro-survival protein Bcl-XL. Besides the conventional antiapoptotic function, Bcl-XL has recently been shown to stabilize G2/M cell cycle arrest through direct interaction with CDC2 (Schmitt et al., 2007) . Analogous to cyclin D2, FoxO-induced Bcl-6 activation represses Bcl-XL at the transcriptional level (Tang et al., 2002) . The activation of FoxO1 by CPT-11 is impeded by CDK2 which phosphorylates FoxO1, causing the nuclear exclusion of the transcription factor . As CDK2 is a critical component in S phase cell cycle entry, its direct role in antagonizing the cytostatic effect of CPT-11 indicates that FoxO is an integration point between cell cycle checkpoint and apoptosis.
The above examples illustrate that loss of FoxO activity may result in a reduction of sensitivity of cancer cells to cytotoxic drugs through a loss of cell cycle regulation (Sunters et al., 2003 (Sunters et al., , 2006 . In a number of circumstances, cancer cells may be sensitized to chemotherapeutic drugs by the reintroduction or reactivation of FoxO to restore cell cycle control. For example, FoxO3a has been identified as a critical cellular target of gefitinib (Iressa), a small molecule inhibitor of epidermal growth factor receptor, which causes growth delay in cancer cell lines and human tumour xenografts expressing high levels of epidermal growth factor receptor (Krol et al., 2007) . In resistant breast cancer cells, reintroduction of active FoxO3a can partially restore cell proliferative arrest and sensitivity to gefitinib. In line with this observation, it has also been shown that the introduction of an active form of FoxO4 sensitizes HER2-overexpressing cells to apoptosis induced by the chemotherapeutic agent 2-methoxyestradiol, and it is believed that the restoration of FoxO4-induced p27 Kip1 is at least in part responsible for such observation (Yang et al., 2005) .
An emerging theme is that the consequences of FoxO3a activation depends on cellular environment and can lead to a switch in FoxO3a-mediated gene expression profile. The antiproliferative and proapoptotic compound 3,3 0 -diindolylmethane has been reported to regulate PKB and androgen receptor in prostate cancer cells. Interestingly, treatment of prostate cancer cell lines with 3,3 0 -diindolylmethane inhibits FoxO3a phosphorylation and binding of FoxO3a to the promoter of AR, while promoting binding of FoxO3a to the p27 Kip1 promoter, thus changing androgen receptor and p27
Kip1 expression, leading to the inhibition of cell proliferation and the induction of apoptosis. A mechanism by which FoxO3a has been reported to differentially affect target gene expression is through the recruitment of histone deacetylase to the FoxO3a-p300/CBP complex, an event which has been hypothesized to differentially affect FoxO3a target gene expression (Brunet et al., 2004; van der Heide and Smidt, 2005) . Sirtuins, the nicotinamide adenine dinucleotide þ -dependent protein deacetylases, have been proposed to repress apoptosis and counteract oxidative and genotoxic stresses via FoxO (Brunet et al., 2004; Kobayashi et al., 2005) . Moreover, inhibition of HDACs has been reported to induce growth arrest, activation of apoptotic pathways, autophagic cell death and senescence in transformed cells (Xu et al., 2007) . This raises the possibility that inhibition of sirtuin activity may also sensitize cancer cells to chemotherapeutic drugs through favouring apoptosis over stress resistance following cell cycle arrest induced by FoxO activation (Lam et al., 2006; Myatt and Lam, 2007b) . In summary, the importance of FoxO proteins in cell cycle checkpoint regulation, and subsequent cell-fate determination, supports the applicability of employing FoxO regulation as a future target for therapeutic intervention in cancer.
Conclusions
FoxO proteins play a central role in controlling cell fate (Greer and Brunet, 2005; Lam et al., 2006) . Multiple and divergent signalling pathways converge to influence FoxO activity, the net outcome of which leads to changes in the expression of genes important for cellfate determination, which is rarely observed without accompanying FoxO-induced changes in the cell cycle Figure 3 Cell-fate decisions tied to specific cell cycle phases. The induction of certain cell fate by FoxO is frequently coupled to exit from specific phases of the cell cycle. Cell fates and associated phases are shown. Perturbation of these pathways is often involved in hyperproliferative disorders, including cancer, as well as promoting resistance to cellular stress or apoptosis.
( Figure 3 ). Indeed, cell proliferation, survival, differentiation, tissue and organ development, cell renewal, cellular senescence, organism ageing, metastasis and stress responses are all tied to FoxO-dependent changes in the cell cycle machinery. As such, while FoxO may directly regulate genes important in these processes, such as the pro-apoptotic gene Bim in apoptosis (Dijkers et al., 2000a; Essafi et al., 2005) , modulation of the cell cycle often provides a permissive cellular environment through which cell fate is specified. For example, in the absence of growth or survival stimuli, cells commonly arrest at G1 before withdrawing from the cell cycle (quiescence), and G1 arrest is similarly associated with development, cells undergoing apoptosis, cell differentiation or cellular senescence. In response to stress, arrest at the G1 or G2/M checkpoint may allow for cell detoxification and/or repair preceding cell cycle re-entry. In fact, the absolute dependence of the cell cycle functions of FoxO in these processes has been highlighted by the observation that in both animal and cellular experimental models depletion of FoxO proteins, or their downstream cell cycle targets, including p27 Kip1 , p21
Cip1 and p130 can deregulate cell-fate programmes. The realization of FoxO as a critical regulator of cell-fate determination has paved a new road for future investigation in this field and we believe the next challenge will be defining the mechanism by which FoxO proteins decipher upstream signals to influence cell-fate outcome. In many circumstances, the physiological responses coupled to cell cycle arrest triggered by FoxO transcription factors are likely to be determined by the cellular context, the developmental status, the intensity or duration of the signal and the cofactors involved. Undoubtedly, advances in the coming years should greatly aid the quest of understanding these exciting signalling pathways and their clinical implications.
